Literature DB >> 35859883

Designing a Small Fluorescent Inhibitor to Investigate Soluble Epoxide Hydrolase Engagement in Living Cells.

Steffen Brunst1, Julia Schönfeld1, Peter Breunig2, Luisa D Burgers3, Murphy DeMeglio2, Johanna H M Ehrler1, Felix F Lillich1, Lilia Weizel1, Jasmin K Hefendehl2, Robert Fürst3, Ewgenij Proschak1, Kerstin Hiesinger1.   

Abstract

Soluble epoxide hydrolase (sEH) is a promising target for a number of inflammation-related diseases. In addition, inhibition of sEH has been shown to reduce neuroinflammation, which plays a critical role in the development of central nervous system (CNS) diseases such as Alzheimer's disease. In this study, we present the rational design of a small fluorescent sEH inhibitor. Starting from the clinical candidate GSK2256294A, we replaced the triazine moiety with the 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) fluorophore. The resulting fluorescent sEH inhibitor displayed excellent potency in an in vitro enzyme activity assay (IC50 < 2 nM). The developed inhibitor is applicable in a NanoBRET-based assay system suitable for studying sEH target engagement in living cells. Furthermore, the inhibitor can be used to visualize sEH in sEH-transfected HEK293 cells and in primary mouse astrocytes by fluorescence microscopy.
© 2022 The Authors. Published by American Chemical Society.

Entities:  

Year:  2022        PMID: 35859883      PMCID: PMC9290038          DOI: 10.1021/acsmedchemlett.2c00073

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  30 in total

1.  Development of a high throughput cell-based assay for soluble epoxide hydrolase using BacMam technology.

Authors:  Wensheng Xie; Xiaoyan Tang; Quinn Lu; Robert S Ames; Steven J Ratcliffe; Hu Li
Journal:  Mol Biotechnol       Date:  2010-07       Impact factor: 2.695

2.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases.

Authors:  Christophe Morisseau; Marvin H Goodrow; John W Newman; Craig E Wheelock; Deanna L Dowdy; Bruce D Hammock
Journal:  Biochem Pharmacol       Date:  2002-05-01       Impact factor: 5.858

3.  1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Authors:  Tristan E Rose; Christophe Morisseau; Jun-Yan Liu; Bora Inceoglu; Paul D Jones; James R Sanborn; Bruce D Hammock
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

4.  Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues.

Authors:  Ahmed E Enayetallah; Richard A French; Michele Barber; David F Grant
Journal:  J Histochem Cytochem       Date:  2005-11-28       Impact factor: 2.479

Review 5.  Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade.

Authors:  Malliga R Iyer; Biswajit Kundu; Casey M Wood
Journal:  Expert Opin Ther Pat       Date:  2022-04-12       Impact factor: 6.674

6.  Structure-Based Design of Dual Partial Peroxisome Proliferator-Activated Receptor γ Agonists/Soluble Epoxide Hydrolase Inhibitors.

Authors:  Felix F Lillich; Sabine Willems; Xiaomin Ni; Whitney Kilu; Carmen Borkowsky; Mirko Brodsky; Jan S Kramer; Steffen Brunst; Victor Hernandez-Olmos; Jan Heering; Simone Schierle; Roxane-I Kestner; Franziska M Mayser; Moritz Helmstädter; Tamara Göbel; Lilia Weizel; Dmitry Namgaladze; Astrid Kaiser; Dieter Steinhilber; Waltraud Pfeilschifter; Astrid S Kahnt; Anna Proschak; Apirat Chaikuad; Stefan Knapp; Daniel Merk; Ewgenij Proschak
Journal:  J Med Chem       Date:  2021-11-24       Impact factor: 7.446

Review 7.  Phosphatase activity of soluble epoxide hydrolase.

Authors:  Jan Kramer; Ewgenij Proschak
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-07-17       Impact factor: 3.072

8.  A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage.

Authors:  Ross P Martini; Dominic Siler; Justin Cetas; Nabil J Alkayed; Elyse Allen; Miriam M Treggiari
Journal:  Neurocrit Care       Date:  2021-12-06       Impact factor: 3.210

Review 9.  The Multifaceted Role of Epoxide Hydrolases in Human Health and Disease.

Authors:  Jérémie Gautheron; Isabelle Jéru
Journal:  Int J Mol Sci       Date:  2020-12-22       Impact factor: 5.923

10.  Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.

Authors:  Bruce D Hammock; Cindy B McReynolds; Karen Wagner; Alan Buckpitt; Irene Cortes-Puch; Glenn Croston; Kin Sing Stephen Lee; Jun Yang; William K Schmidt; Sung Hee Hwang
Journal:  J Med Chem       Date:  2021-02-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.